Trials in Louisiana.
38 APOE4-relevant Alzheimer’s trials run in Louisiana — 14 of them recruiting. Each one translated into plain English, with our read on what it means for an APOE4 carrier.
- Non-carriers only, not for APOE4NCT00574132Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)
This trial tested bapineuzumab, an infused antibody designed to bind and clear beta amyloid from the brain, against a placebo. It measured whether it helped…
- Drug trial for diagnosed APOE4 carriersNCT00575055Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)
This trial tested whether bapineuzumab, an antibody given by infusion that helps clear beta amyloid from the brain, could affect thinking and daily function in…
- Built exclusively for APOE4/4 carriersNCT04770220An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
This Phase 3 trial is testing ALZ-801, an oral drug designed to reduce toxic amyloid clusters in the brain, against a placebo in people with early Alzheimer's…
- Drug trial, genotype not specified in sourceNCT00667810Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
This trial tested bapineuzumab, an antibody drug given by infusion, against a placebo in people with mild to moderate Alzheimer's. It looked at how well the…
- Drug trial, not APOE4-specific, carriers at riskNCT00676143Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients
This trial tested bapineuzumab, an antibody drug given by infusion, against a placebo in people with mild to moderate Alzheimer's. Researchers measured safety…
- Drug extension study, prior participants onlyNCT00998764A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients
This trial looked at the long-term safety and tolerability of bapineuzumab, an antibody drug given by infusion, in people with Alzheimer's who had finished an…
- Amyloid-focused, drug did not succeedNCT02008357Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
This Phase 3 trial tested solanezumab, an antibody drug given by IV infusion, in cognitively normal older adults who already had amyloid buildup in their…
- Heart trial, genotype not relevantNCT02884206Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction
This Phase 3 trial tested whether LCZ696 (sacubitril/valsartan, sold as Entresto) protects cognitive function better than valsartan alone in people with a…
- Observational only, no treatment involvedNCT02951598A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)
This study is not testing a treatment. It is an observational study tracking how people with early-stage Alzheimer's disease or MCI use health care, what that…
- Cancer patients only, genotype not specifiedNCT03016741Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer
This trial is studying whether prostate cancer hormone therapies — specifically abiraterone acetate and enzalutamide — affect brain structure and cognitive…
- Lifestyle study, not APOE4-specificNCT03890861Reducing African Americans' Alzheimer's Disease Risk Through Exercise (RAATE)"
This study tests whether a physical activity program designed for older African American adults changes memory and executive function (planning and mental…
- Not APOE4-related, movement disorder focusNCT03924414Trial of Parkinson's And Zoledronic Acid
This trial is testing whether a single IV infusion of zoledronic acid, a bone-strengthening drug already approved for osteoporosis, can reduce fractures in…
- Open to carriers, genotype not trackedNCT04098666Metformin in Alzheimer's Dementia Prevention
This trial is testing whether extended-release metformin, a widely used diabetes drug, can slow memory decline in people who are overweight and already showing…
- Open to carriers, not 4-specificNCT04262206Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
PREVENTABLE is a large Phase 4 trial testing whether atorvastatin 40 mg — a common cholesterol-lowering statin — can reduce the combined risk of death,…
- Lifestyle study, genotype not requiredNCT04956549Reducing African American's Alzheimer's Risk Through Exercise-Mild Cognitive Impairment (RAATE-MCI)
This trial is testing whether a structured physical activity program can reduce Alzheimer's risk factors in older African American adults who already have mild…
- Drug trial, genotype not specified, ARIA riskNCT05026866A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
This trial tests donanemab, an anti-amyloid antibody given by infusion, against a placebo in people with no memory or thinking problems but signs of amyloid in…
- Biomarker study, not APOE4-specificNCT05060848Plasma Hydrogen Sulfide as a Biomarker for Alzheimer's Disease and Related Dementias
This study measures hydrogen sulfide, a molecule tied to blood vessel health, in blood samples. Researchers will compare levels in people with and without…
- Anti-amyloid drug — carriers face higher ARIA riskNCT05463731A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
This Phase 3 trial is testing remternetug, an anti-amyloid antibody given by IV or injection under the skin, in people with early symptomatic Alzheimer's…
- Open to carriers, not 4-specificNCT05479552A Diagnostic Test for Dementia With Lewy Bodies
This study is testing a diagnostic tool called the Syn-One Test, which looks for a protein called alpha-synuclein in a skin biopsy. The goal is to better…
- Early Alzheimer's drug trial, not 4-specificNCT05531526Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)
This trial tests whether a pill called AR1001 can slow memory and thinking decline in people with early Alzheimer's, compared with a placebo. It also checks…
- Symptom drug trial, not APOE4-specificNCT05543681Clinical Trial on Agitation in Alzheimer's Dementia
This trial tests whether IGC-AD1, a twice-daily oral THC-based medication, can ease agitation in people with mild to severe Alzheimer's dementia. Agitation…
- Late-stage dementia care, genotype not relevantNCT05644262Life's End Benefits of cannaBidiol and tetrahYdrocannabinol
This Phase 2 trial is testing whether a liquid oral combination of THC and CBD (the two main active compounds in cannabis) can reduce agitation in people with…
- Late-stage AD only, genotype not relevantNCT05980949Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
This trial is testing whether KarXT, a drug targeting certain brain receptors, is safe to take for up to a year in people who already have Alzheimer's-related…
- Open to carriers, not 4-specificNCT06126224A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
This Phase 3 trial is testing KarXT, a drug that targets muscarinic receptors in the brain, against a placebo in people aged 55 to 90 who have Alzheimer's…
- Symptom drug trial, not APOE4-specificNCT06159673ACP-204 in Adults With Alzheimer's Disease Psychosis
This trial tests ACP-204, a daily pill, against a placebo in people with Alzheimer's disease who have developed psychosis, such as hallucinations or delusions.…
- Drug trial, APOE4 handling not statedNCT06653153A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
This trial tests remternetug, an anti-amyloid antibody drug, against a placebo. It measures how long it takes for memory, thinking, or daily-function problems…
- Drug trial, genotype not specifiedNCT06709014A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD
This trial tests whether buntanetap, a daily pill, slows memory and thinking decline and helps everyday function in adults 55 to 85 with early Alzheimer's. It…
- Open to carriers, not 4-specificNCT06721156A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)
This trial is testing MK-1167, an experimental drug given alongside a standard Alzheimer's medication called an acetylcholinesterase inhibitor. Researchers…
- Open to carriers, not 4-specificNCT06808984Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
This trial tests BMS-986368, an experimental drug that works on the body's endocannabinoid system, to see whether it reduces agitation in people who already…
- Open to carriers, not 4-specificNCT06847321Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
This Phase 2 trial is testing LHP588, an oral capsule taken once daily, in people with mild to moderate Alzheimer's disease who also test positive for P.…
- Drug trial, not for healthy carriersNCT06887192A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
This trial tests a drug called ML-007C-MA against a placebo in people aged 55 to 90 who already have Alzheimer's and are troubled by hallucinations and…
- Open to carriers, not 4-specificNCT07011732A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
This trial is testing two drug combinations — KarXT (xanomeline plus trospium) and KarX-EC — to see whether they reduce agitation in people with confirmed…
- Carriers tracked, ARIA risk significantNCT07169578A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
This trial is testing trontinemab, an anti-amyloid antibody drug, against a placebo in people with early Alzheimer's disease — specifically those at the MCI or…
- Gateway study, genotype not specifiedNCT07177352Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
This is not a treatment trial. It is a pre-screening study run by Roche to figure out who might qualify for their future Alzheimer's disease trials.…
- General aging study, genotype not addressedNCT07224347Aspirin in Reducing Events in the Elderly-Extension (ASPREE-XT)
ASPREE-XT is following older adults who were previously in the ASPREE aspirin trial to see what happens after they stopped taking aspirin. Researchers are…
- For diagnosed Alzheimer's, not APOE4-specificNCT07265323Effect of Physiologic Insulin Administration on Insulin Sensitivity and Cognition
This trial tests whether short weekly insulin sessions, each lasting up to 2 hours for 6 months, change how the body uses glucose and affect memory and…
- Not relevant to APOE4 carriersNCT07498426A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
This trial is testing NIO752, an experimental drug, in people diagnosed with Progressive Supranuclear Palsy Richardson Syndrome — a rare and serious brain…
- Prior participants only, not APOE4-specificNCT07602582A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
This Phase 3 trial tests whether people who already took donanemab in an earlier study (TRAILBLAZER-ALZ 3) get clinical benefit from yearly doses compared with…
Copy a forum-ready post
Keep exploring
Educational, not medical advice. Trial decisions belong between you and your physician.